Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.

JCO precision oncology - 1 Jan 2021

Spengler Marianne, Wheelden Megan, Mackley Heath B, Drabick Joseph J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fumarate Hydratase
Share to Indazoles
Share to Nasal Cavity
Share to Nose Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrimidines

Share to Remission Induction

Share to Retreatment

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34036225
DOI: 10.1200/PO.20.00486
PMCID: PMC8140788

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.PMID 34036225Read ↗

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation.Semantic proximity Read ↗

Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment.Semantic proximity Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAFV600E mutation.Semantic proximity Read ↗

Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor.Semantic proximity Read ↗

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.Semantic proximity Read ↗

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?Semantic proximity Read ↗

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.